Review Article
New Treatment in Advanced Thyroid Cancer
Table 1
Most frequent (all grade) adverse events of tyrosine kinase inhibitors used in thyroid cancer.
| | Adverse event | Sunitinib
[37, 39] | Sorafenib
[41–45] | Vandetanib
[47–49] | Motesanib
[50] | Axitinib
[53] | Pazopanib
[55] | Lenvatinib
[58] |
| Hypertension
| 22% | 48% | 33% | 27% | 28% | — | 64% | Diarrhea
| 37% | 77% | 57% | 41% | 48% | 73% | 45% | Fatigue
| 45% | 48% | 43% | 41% | 50% | 78% | 55% | Weight loss
| — | 54% | 30% | 22% | 25% | 64% | 43% | Nausea
| — | 22% | 37% | 26% | 33% | 73% | 44% | Hand-foot skin reaction
| 35% | 91% | — | — | 15% | — | — | | Rash | — | 73% | 46% | — | 15% | 75% | — |
|
|
